Co-transplantation of Stromal Cells Interferes with the Rejection of Allogeneic Islet Grafts

Authors

  • Stella Jacobson,

    1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for more papers by this author
  • Makiko Kumagai-Braesch,

    1. Division of Transplantation Surgery, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for more papers by this author
  • Annika Tibell,

    1. Division of Transplantation Surgery, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for more papers by this author
  • Mattias Svensson,

    1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for more papers by this author
  • Malin Flodström-Tullberg

    1. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Search for more papers by this author

Address for correspondence: Malin Flodström Tullberg, Ph.D., Center for Infectious Medicine F59, Department of Medicine, Karolinska Institutet, Huddinge University Hospital, S-141 86, Stockholm, Sweden. Voice: +46 8 585 89681; fax: +46 8 746 7637. malin.flodstrom-tullberg@ki.se

Abstract

Side effects associated with current immunosuppressive therapy complicate the use of islet transplantation as a treatment for type 1 diabetes. Multipotent mesenchymal stromal cells (MSCs) have demonstrated immunomodulatory activity. The purpose of this study was to investigate whether a murine stromal cell line affects graft rejection in a fully major histocompatibility complex (MHC)-mismatched islet transplant model. We show that stromal cells have an inhibitory effect on T cell proliferation in vitro, and that they slow down the rejection of allogeneic islets. These findings indicate a possibility to use MSCs as a treatment to prolong the survival of islet grafts.

Ancillary